CytomX Therapeutics (CTMX) Retained Earnings (2016 - 2025)
Historic Retained Earnings for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$682.4 million.
- CytomX Therapeutics' Retained Earnings rose 394.37% to -$682.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$682.4 million, marking a year-over-year increase of 394.37%. This contributed to the annual value of -$691.6 million for FY2024, which is 440.52% up from last year.
- CytomX Therapeutics' Retained Earnings amounted to -$682.4 million in Q3 2025, which was up 394.37% from -$668.2 million recorded in Q2 2025.
- In the past 5 years, CytomX Therapeutics' Retained Earnings ranged from a high of -$531.0 million in Q1 2021 and a low of -$727.3 million during Q2 2023
- Moreover, its 5-year median value for Retained Earnings was -$691.6 million (2024), whereas its average is -$675.1 million.
- Per our database at Business Quant, CytomX Therapeutics' Retained Earnings crashed by 3521.34% in 2021 and then soared by 669.97% in 2025.
- Quarter analysis of 5 years shows CytomX Therapeutics' Retained Earnings stood at -$623.6 million in 2021, then decreased by 15.93% to -$722.9 million in 2022, then dropped by 0.08% to -$723.4 million in 2023, then grew by 4.41% to -$691.6 million in 2024, then grew by 1.32% to -$682.4 million in 2025.
- Its last three reported values are -$682.4 million in Q3 2025, -$668.2 million for Q2 2025, and -$668.1 million during Q1 2025.